← Leaderboards
Robert Griffin
Rejuvenics Technologies, Llc
$438,213
Attributed
$438,213
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $383.2K · FY2020–21$500K$375K$250K$125K$0
'20
'21
Funding mix
By agency
NIH$438,213 · 1
By mechanism
N44$383,213 · 1
N43$55,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Antineoplastic Agents”
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Leonard Freedmand · Leidos Biomedical Research, Inc.$54,796,285
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$29,626,259
- James Jeffrey Sahn · 4e Therapeutics Inc.$7,126,294
- Jeffrey H. Price · Vala Sciences, Inc.$5,562,326
Research focus
Antineoplastic AgentsArkansasBiodistributionCancer PatientChemotherapeutic AgentChemotherapyChemotherapy And/Or RadiationCollaborationsCommercializationDrug DevelopmentDrug KineticsEncapsulatedExposure ToIndustryIonizing RadiationLeadLegal PatentLewis Lung CarcinomaLiposomesMalignant Neoplasm Of LungMedicalMethodologyNonmetastaticOrgan